TFF3 and esophageal adenocarcinoma: Randomised controlled trial data from the BEST3 study has shown that offering a novel non-endoscopic test, the Cytosponge-trefoil factor 3 (TFF3), in the primary care setting in England can diagnose ten times more Barrett esophagus than usual care over a year.